Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
Open Access
- 31 August 2020
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-11
Abstract
Background: We describe the clinical benefit of immune checkpoint inhibitors using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and ASCO VF. Methods: We identify all approved indications of immune checkpoint inhibitors based on RCTs between January 1, 2011 and September 30, 2018 by FDA. Information including medians and HR of OS (PFS or DFS) and 95% CI, grade 3 or 4 toxicities in each arm, QOL data, survival probability at fixed time were extracted. Results: Immune checkpoint inhibitors were approved for 18 indications based on RCTs. All the indications meet the ESMO-MCBS 1.1 threshold for meaningful benefit. By the updated ASCO-VF, the median Net Health Benefit (NHB) of these agents was 55.3 (range 17.4–77.1). Two third of the indication gained the bonus points for durable survival benefits by updated ASCO VF. When updated results were incorporated in the assessment, clinical benefit of most approved immune checkpoint inhibitors increased with a median improvement of NHB of 10 (range 2–20). Conclusions: Approved immune checkpoint inhibitors provided clinical meaningful benefit by ESMO-MCBS 1.1, and most of these agents reach the threshold for bonus points for durable survival in the updated ASCO VF.Keywords
This publication has 29 references indexed in Scilit:
- Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research GroupsJNCI Cancer Spectrum, 2018
- Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial CancerJournal of Clinical Oncology, 2018
- Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug AdministrationJNCI: Journal of the National Cancer Institute, 2017
- Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trialThe Lancet Oncology, 2017
- ESMO-Magnitude of Clinical Benefit Scale version 1.1Annals of Oncology, 2017
- Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworksThe Lancet Oncology, 2017
- Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic DrugsJournal of Oncology Practice, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 studyAnnals of Oncology, 2016
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015